Christopher Severson
Brigham and Women's Hospital
18 Papers
Christopher Severson is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Internal medicine & Multiple sclerosis. The author has an hindex of 9, co-authored 11 publications. Previous affiliations of Christopher Severson include Harvard University.
Chat about Author
Papers
Phase 2 trial of ibudilast in progressive multiple sclerosis
Robert J. Fox,Christopher S. Coffey,Robin Conwit,Merit Cudkowicz,Trevis Gleason,Andrew D. Goodman,Eric C. Klawiter,K. Matsuda,Michelle McGovern,Robert T. Naismith,Akshata Ashokkumar,Janel Barnes,Dixie Ecklund,Elizabeth A. Klingner,Maxine Koepp,Jeffrey D. Long,Sneha Natarajan,Brenda Thornell,Jon W. Yankey,Robert A. Bermel,J. P. Debbins,X. Huang,P. Jagodnik,Mark J. Lowe,Kunio Nakamura,S. Narayanan,Kenneth Earl Sakaie,B. Thoomukuntla,X. Zhou,Stephen Krieger,Enrique Alvarez,Michelle L Apperson,Khurram Bashir,Bruce A. Cohen,P. K. Coyle,Silvia Delgado,L. D. Dewitt,A. Flores,Barbara Giesser,Myla D. Goldman,Burk Jubelt,Neil Lava,Sharon G. Lynch,Harold L. Moses,Daniel Ontaneda,Jai Perumal,Michael K. Racke,Michael K. Racke,Pavle Repovic,Claire S Riley,Christopher Severson,Shlomo Shinnar,Valerie Suski,Bianca Weinstock-Guttman,Vijayshree Yadav,Aram Zabeti +55 more
TL;DR: In a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associatedWith higher rates of gastrointestinal side effects, headache, and depression.
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruce A.C. Cree,Gary Cutter,Jerry S. Wolinsky,M. S. Freedman,Giancarlo Comi,Gavin Giovannoni,Hans-Peter Hartung,Douglas L. Arnold,Jens Kuhle,Valerie J Block,Frederick E. Munschauer,Frédéric Sedel,Fred D. Lublin,Stephen C. Reingold,Pierre Duquette,Tobias Derfuss,Franz Fazekas,Maria Pia Sormani,Robert P. Lisak,Jennifer Graves,Stephen Krieger,Rana K. Zabad,Scott D. Newsome,Joshua Barton,Richard MacDonell,Mark Marriott,Nina De Klippel,Guy Laureys,Barbara Willekens,Virginia Devonshire,Mark S. Freedman,J. Marc Girard,Paul S. Giacomini,Roger McKelvey,Daniel Selchen,Galina Vorobeychik,Ludivine Witkowski,Radek Ampapa,Jana Lizrova Preiningerova,Eva Meluzinova,R. Talab,Marta Vachova,Orhan Aktas,Mathias Buttmann,Elias Hamp Birte,Tania Kuempfel,Paul Friedemann,Daniela Rau,Gerd Reifschneider,Piotr Sokolowski,Hayrettin Tumani,Maria Satori,Carlo Pozzilli,Agata Klosek,Jozef Koscielniak,Fryze Waldemar,Malgorzata Zajda,Rafael Arroyo Gonzalez,Guillermo Izquierdo Ayuso,Victoria Fernandez Sanchez,Celia Oreja Guevara,Jose Enrique Martinez Rodriguez,Xavier Montalban,Lluís Ramió-Torrentà,Lou Brundin,Jan Lycke,Murat Terzi,Joe Guadagno,Don J. Mahad,Adrian Pace,Klaus Schmierer,Ahmed T. Toosy,Stewart Webb,Mark A. Agius,Lilyana Amezcua,Michelle L Apperson,Bridget Bagert,Daniel Bandari,Evanthia Bernitsas,Jonathan Calkwood,Jonathan Carter,Bruce A. Cohen,Devon S. Conway,Joanna Cooper,John R. Corboy,Patricia K. Coyle,Bruce C.A. Cree,Mitchel Freedman,Corey C. Ford,Edward Fox,Myla D. Goldman,Benjamin Greenberg,Mariko Kita,Thomas Leist,Sharon G. Lynch,Aaron E. Miller,Harold L. Moses,Robert T. Naismith,Mary Ann Picone,Bhatia Perminder,Alexander Rae-Grant,Kottil Rammohan,Anthony T. Reder,Claire S Riley,Derrick Robertson,Vernon Rowe,Shiv Saidha,Lawrence Samkoff,Christopher Severson,Kyle Smoot,Sharon Stoll,Randall Trudell,Bianca Weinstock-Guttman,Sanjay Yathiraj +113 more
TL;DR: This study showed that MD 1003 did not significantly improve disability or walking speed in patients with progressive multiple sclerosis and thus, in addition to the potential of MD1003 for deleterious health consequences from interference of laboratory tests, MD1002 cannot be recommended for treatment of progressive multipleclerosis.
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis
Robert J. Fox,Christopher S. Coffey,Merit Cudkowicz,Trevis Gleason,Andrew D. Goodman,Eric C. Klawiter,Kazuko Matsuda,Michelle McGovern,Robin Conwit,Robert T. Naismith,Akshata Ashokkumar,Robert A. Bermel,Dixie Ecklund,Maxine Koepp,Jeffrey D. Long,Sneha Natarajan,Srividya Ramachandran,Thomai Skaramagas,Brenda Thornell,Jon W. Yankey,Mark A. Agius,Mark A. Agius,Khurram Bashir,Bruce A. Cohen,Patricia K. Coyle,Silvia Delgado,Dana Dewitt,Angela Flores,Barbara Giesser,Myla D. Goldman,Burk Jubelt,Neil Lava,Sharon G. Lynch,Augusto Miravalle,Harold L. Moses,Daniel Ontaneda,Jai Perumal,Michael K. Racke,Pavle Repovic,Claire S Riley,Christopher Severson,Shlomo Shinnar,Valerie Suski,Bianca Weinstock-Gutman,Vijayshree Yadav,Aram Zabeti +45 more
TL;DR: The SPRINT-MS study is designed to evaluate the safety and efficacy of ibudilast as a treatment for PMS while simultaneously validating five different imaging biomarkers as outcome metrics for use in future phase II proof-of-concept PMS trials.
64
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
Kathryn B. Holroyd,Brian C. Healy,Sarah E. Conway,Maria K. Houtchens,Rohit Bakshi,Shamik Bhattacharyya,Gauruv Bose,Kristin M. Galetta,Tamara B. Kaplan,Christopher Severson,Tarun Singhal,Lynn Stazzone,Jonathan Zurawski,Mariann Polgar-Turcsanyi,Shrishti Saxena,Anu Paul,Bonnie I. Glanz,Howard L. Weiner,Tanuja Chitnis +18 more
TL;DR: In this paper , the authors investigated the effect of anti-CD20 and sphingosine-1-phosphate (S1P) modulators on the risk of severe Coronavirus Disease 19 (COVID-19) and death.
26
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2
Rohit Bakshi,Mohit Neema,Shahamat Tauhid,Brian C. Healy,Bonnie I. Glanz,Gloria Kim,Jennifer Miller,Julia L. Berkowitz,Riley Bove,Maria K. Houtchens,Christopher Severson,James Stankiewicz,Lynn Stazzone,Tanuja Chitnis,Charles R.G. Guttmann,Howard L. Weiner,Antonia Ceccarelli +16 more
TL;DR: A new version of the MRDSS, which has been expanded to include cerebral gray matter and spinal cord involvement from 3 T MRI, has concurrent validity with clinical status and showed a larger effect size than its individual components in comparing cognitively impaired with cognitively preserved patients.